Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. The company is a clinical stage bio-pharmaceutical company and earns its revenues from license fee/ royalty on technology and R&D services.
- Sun Pharma Advanced Research Company reported Total revenue for Q4 FY23 of ₹48 Crore, up from ₹25 Crore year on year depicting a growth of 92%.
- Total Expenses for Q4 FY23 of ₹137 Crore up, from ₹92 Crore year on year, a growth of 49%.
- Consolidated Net Profit of -(₹82) Crore, down 15% from -(₹71) Crore in the same quarter of the previous year.
- The Earnings per Share is -(₹2.53), up 3% from -(₹2.61) in the same quarter of the previous year.
